Positive Ph 2 Preliminary Data of SLS009 in R/R AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation at the Optimal Dose Level Announced May 7, 2024
Positive Recommendation of IDMC Following Completion of Enrollment in REGAL Ph 3 Study Announced May 1, 2024
Successful Completion of Higher Dose Second Cohort in Ph 1/1b Trial of BP1002 in R/R AML Patients April 23, 2024
EBMT 2024: Iomab-B Overcomes High-Risk TP53 Mutation Resulting in Significant OS Improvement in R/R AML Patients April 23, 2024
FDA Orphan Drug Designation and completion of FDA INTERACT meeting for BVX001 in the treatment of AML announced April 23, 2024
Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression April 16, 2024
FDA accepts NDA for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers April 16, 2024
Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML published in Leukemia & Lymphoma April 8, 2024
Steering Committee Update Provided on Ph 3 REGAL Study with Positive Topline Data Announcement from Ph 2a Study of SLS009 in R/R AML April 2, 2024
Completion of Enrollment Announced in AUGMENT-101 Pivotal Trial Cohort of Patients with R/R mNPM1 AML April 2, 2024
Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy Announced April 2, 2024
Enrollment Initiated in 12-Patient Expansion Cohort of Voruciclib + Venetoclax in Ongoing Ph 1 Study April 2, 2024
Progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia reported April 2, 2024
FDA Priority Review of NDA for Revumenib for the Treatment of R/R KMT2Ar Acute Leukemia April 2, 2024
Additional Positive Data announced from Ph 1 Part of BEXMAB Study in Both Higher-Risk HMA-Failed MDS and R/R AML March 26, 2024
FDA grants accelerated approval to ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL March 26, 2024
Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia March 19, 2024
